Encapsulated Papillary Carcinoma of the Breast: Two Cases with Literature Review and Molecular Insights.
1/5 보강
[INTRODUCTION] Encapsulated papillary carcinoma (EPC) of the breast is a rare subtype of breast cancer, accounting for 0.5-2% of cases, and typically affects postmenopausal women.
APA
Baboli KM, Salehiazar S, Tran T (2026). Encapsulated Papillary Carcinoma of the Breast: Two Cases with Literature Review and Molecular Insights.. Rhode Island medical journal (2013), 109(2), 7-10.
MLA
Baboli KM, et al.. "Encapsulated Papillary Carcinoma of the Breast: Two Cases with Literature Review and Molecular Insights.." Rhode Island medical journal (2013), vol. 109, no. 2, 2026, pp. 7-10.
PMID
41592189 ↗
Abstract 한글 요약
[INTRODUCTION] Encapsulated papillary carcinoma (EPC) of the breast is a rare subtype of breast cancer, accounting for 0.5-2% of cases, and typically affects postmenopausal women. Characterized by well-circumscribed lesions lacking peripheral and central myoepithelial cells, EPC is associated with favorable prognosis due to its indolent behavior and high hormone receptor positivity. However, its potential association with ductal carcinoma in situ (DCIS) or invasive carcinoma necessitates thorough diagnostic evaluation.
[CASE PRESENTATION] This study presents two cases of EPC-one in a 57-year-old and the other in a 39-year-old female-each with focal DCIS and strong estrogen and progesterone receptor expression. Both patients underwent breast-conserving surgery and were managed with hormone therapy.
[CONCLUSION] Histopathological and immunohistochemical analyses confirmed the EPC diagnosis, and molecular insights revealed common mutations, particularly in the PIK3CA gene. This report underscores the importance of integrating clinical, histological, and molecular findings to guide diagnosis and management of EPC, which, despite its low invasive potential, shares genetic features with invasive ductal carcinoma.
[CASE PRESENTATION] This study presents two cases of EPC-one in a 57-year-old and the other in a 39-year-old female-each with focal DCIS and strong estrogen and progesterone receptor expression. Both patients underwent breast-conserving surgery and were managed with hormone therapy.
[CONCLUSION] Histopathological and immunohistochemical analyses confirmed the EPC diagnosis, and molecular insights revealed common mutations, particularly in the PIK3CA gene. This report underscores the importance of integrating clinical, histological, and molecular findings to guide diagnosis and management of EPC, which, despite its low invasive potential, shares genetic features with invasive ductal carcinoma.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.